Comparing a new treatment for shoulder tendon injuries with traditional rehab methods

Comparison of the treatment effects of nonreactive tendinopathy of the supraspinatus tendon: treatment with percutaneous tendon electrolysis, which is responsible for the conservative and control rule

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN66866842

Enrollment

Registered

2025-03-25

Start date

2024-12-10

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment of rotator cuff tendinopathy Musculoskeletal Diseases

Interventions

The research group meeting the criteria will be divided into three groups of 30 participants. Each participant will have their range of motion in the glenohumeral joint measured with an inclinometer b

Eligibility

Sex/Gender

All

Age

35 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Patients with clinical symptoms of supraspinatus tendon tendinopathy, visible and confirmed tendinopathy of this tendon in an imaging study (USG and/or MRI) 2. Duration of symptoms between 3 months and 2 years 3. Women and men 4. Age: 35 to 55 years

Exclusion criteria

Exclusion criteria: Coexisting tendinopathies of other rotator cuff tendons, subacromial-subdeltoid bursitis, secondary tendinopathy after supraspinatus tendon reconstruction or report a mechanical injury in the interview, calcification tendinopathy of the supraspinatus tendon (tendon calcification). The study will include patients regardless of the extent of tendinopathic changes in the tendon and the location of these changes in the tendon.

Design outcomes

Primary

Measure	Time frame
Assessed at baseline and 6 weeks of treatment: 1. Muscle tension (F = Hz), stiffness (S = N/m), flexibility and relaxation (ms) were measured using a myotonometer (MyotonPRO AS, Myoton Ltd, Estonia 2021) 2. Muscle pain threshold (PT-kG or N) was measured using a FDIX algesimeter (Wagner Instruments, Greenwich, CT, USA 2013) 3. Muscle strength (W) was measured using a handheld dynamometer (EH106 China 2020) 4. Range of Motion was measured using a K-Force Move v3 – electronic goniometer (Italy 2021) All measurements taken between 10 a.m. and 12 p.m. Measurements are performed on the following muscles: deltoid, supraspinatus, infraspinatus, levator scapulae, equinocostal, sternocleidomastoid, subscapularis, teres minor major, biceps brachii and triceps brachii	—

Measure

Time frame

Assessed at baseline and 6 weeks of treatment: 1. Muscle tension (F = Hz), stiffness (S = N/m), flexibility and relaxation (ms) were measured using a myotonometer (MyotonPRO AS, Myoton Ltd, Estonia 2021) 2. Muscle pain threshold (PT-kG or N) was measured using a FDIX algesimeter (Wagner Instruments, Greenwich, CT, USA 2013) 3. Muscle strength (W) was measured using a handheld dynamometer (EH106 China 2020) 4. Range of Motion was measured using a K-Force Move v3 – electronic goniometer (Italy 2021) All measurements taken between 10 a.m. and 12 p.m. Measurements are performed on the following muscles: deltoid, supraspinatus, infraspinatus, levator scapulae, equinocostal, sternocleidomastoid, subscapularis, teres minor major, biceps brachii and triceps brachii

—

Secondary

Measure	Time frame
Assessed at baseline and 6 weeks of treatment: 1. Tendon thickness and bundle length [mm] measured with SONOMED DOPPLER MD4 (China 2020) with a 3-15 MHz transducer 2. Clinical tests (Jobe Test, Full Can Test, Whipple Test) 3. NES numerical pain scale [0-10]	—

Countries

Poland

Contacts

Public ContactRobert TrybulskI

rtrybulski.provita@gmail.com+48 502591428

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jun 11, 2026